Earnings Call · Q2 FY2023·2023-08-01

Q2 23EPS -5.13%·Rev n/aQ1 23EPS -19.48%·Rev n/aQ4 22EPS +7.41%·Rev n/aQ3 22EPS +19.39%·Rev n/a⚠ consensus missing

RHYTHM PHARMACEUTICALS, INC. RYTM

David Connolly — Investor Relations

David Meeker — Chief Executive Officer

Jennifer Chien — Head of Commercial Operations

Yann Mazabraud — International Commercial Lead

Hunter Smith — Chief Financial Officer

+27.5%1d on move date+27.8% vs SPY3d+35.5%5d+39.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RYTM calls or request research access.

More RYTM calls Browse calls Request research access